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ABSTRACT
The human ,B-globin dominant control region (DCR)
which flanks the multigene 3-globin locus directs high
level, site of integration independent, copy number
dependent expression on a linked human ,-globin gene
in transgenic mice and stably transfected mouse
erythroleukemia (MEL) cells. We have assayed each of
the individual DNasel hypersensitve regions present in
the full 15kb DCR for position independence and copy
number dependence of a linked ,3-globin gene in
transgenic mice. The results show that at least three
of the individual DNasel hypersensitive site regions
(sites 1, 2 and 3), though expressing at lower levels
than the full DCR, are capable of position independent,
copy number dependent expression. Site 2 alone
directs the highest level of expression of the single site
constructs, producing nearly 70% of the level of the
full DCR. Sites 1 and 3 each provide 30% of the full
activity. Deletion of either site 2 or 3 from the complete
set significantly reduces the level of expression, but
does not effect position independence or copy number
dependence. This demonstrates that sites 2 and 3 are
required for full expression and suggests that all the
sites are required for the full expression of even a
single gene from this multigene locus.
INTRODUCTION
The human (3-like globin genes are a family of five, closely
linked, active genes arranged in the order of their developmental
expression on the short arm ofchromosome 11 (Fig. 1). Progress
in delineating and defining the function of cis-elements involved
in transcriptional regulation of the human ,B-globin gene has been
achieved through the use of transgenic mice and mouse
erythroleukemia (MEL) cell model systems. Three tissue-specific
regulatory regions, found within and flanking the gene, contain
sufficient information for differentiation- and developmental-stage
specific expression (1,2,3,4). These regions encompass the
promoter and two downstream enhancer elements, located within
the gene and in the 3' flanking region. A number of cis-acting
elements within these regions have been identified which bind
ubiquitous and/or erythroid-specific proteins (5,6,7), the most
notable being the erythroid factor NF-E1 (GF-1, Eryfl) which
has been cloned from human (8), mouse (9) and chicken (10).
Human (-globin gene constructs which contain all these regions
have been shown to result in tissue- and stage-specific expression.
However, the level of expression of the exogenous gene is highly
variable, not dependent on copy number, and occurs at a fraction
of the level of its endogenous counterpart (1,11,12,13). These
phenomena have been attributed to effects of the integration locus
and suggested that insufficient sequence information was present
for fully regulated, position independent expression. Our
laboratory has shown that inclusion ofthe dominant control region
(DCR), confers position independent, high level expression on
a linked ,B-globin gene in MEL cells (14) and transgenic mice
(15). The DCR which is contained in 20kb upstream of the (3-
globin cluster (Fig. la,b) consists of a series of four erythroid
specific DNaseI hypersensitive regions designated 5' to 3', sites
1,2,3,4 (15) or IV, Im, II, I (16), or -18, -14.7, -10.9 and
-6.1 (17). Linkage of the four DNA fragments which span the
individual hypersensitive sites into a micro DCR (Fig. lc) retains
full functional capability, regardless of its orientation relative to
the linked ,B-globin gene (18). The DCR is also capable of
inducing high level expression of a-globin (19,20), y-globin
(21,22) and heterologous genes (15,17).
It is important to point out that the DCR has been assayed in
a number of expression systems with varying results, suggesting
that the individual sites have different functional capabilities.
Transient assays in K562 cells (23) and MEL cells (C-H. Chang
and P. Dierks pers. comm.) have shown enhancer-like activity
in site 3, but not in sites 1,2 or 4. Expression analysis in stably
transformed MEL cell populations has revealed that both sites
2 and 3 are capable of directing high levels of inducible (3-globin
expression, while sites 1 and 4 give lower but significant levels
of activity (24). These results suggest that sites 1, 2 and 4 require
integration into chromatin for their activity to be detected. Results
obtained with a DCR deletion construct in transgenic mice
suggested that at least site 3 can activate the ,B-globin gene,
although it was not clear to what level and whether this provided
position independence (20,25).
In this paper we assess the activity of each of the individual
DNaseI hypersensitive sites (sites 1-4) on a linked (3-globin gene
in transgenic mice. In addition we analyze the expression ofDCR
constructs in which sites 2 or 3 have been deleted from the full
microlocus construct. The results show that the individual sites
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Fig. 1: Schematic illustration of the ,3-globin DCR constructs. (a) The human 3-globin locus on chromosome 11. (b) The original cosmid ;3-globin minilocus as
described in Grosveld et al. (15) was derived using the 5' and 3' elements illustrated. (c) The ,B-globin microlocus cassette containing the four DNaseI hypersensitive
site fragments described in Talbot et al. (18). See Materials and Methods fQr detailed construction. The unique restriction enzyme sites flanking each hypersensitive
site are illustrated. (d) Deletion variants of the microlocus micro-injected into fertilized mouse eggs to produce transgenic mice. Numbers represent the hypersensitive
site(s) present in each construct.
1, 2 and 3 of the DCR provide position independent, copy number
dependent expression and that both sites 2 and 3 are required
for full expression of the human 3-globin gene in transgenic mice.
MATERIALS AND METHODS
Constructs
Construction of the human ,B-globin microlocus cassette and
microlocus deletion mutants was previously described by Coilis
et al. (24). Plasmid constructs were digested with Sstll and
purified from vector sequences on agarose gels.
Transgenic Mice
Purified fragments were microinjected into the pronuclei of
fertilized mouse eggs and implanted into the oviducts of
pseudopregnant (CBAxC57 Bl) Fl female mice (26). Foster
mothers were sacrificed at 13.5 days of gestation and embryos
were collected. Embryos were screened for the presence of the
injected fragment via PCR and/or Southern blotting of placental
DNA. Each transgenic was screened for mosaicism by Southern
blotting of placenta, head and body DNA. Copy numbers were
determined from dilution and Southern blotting of selected
transgenic samples as described in the text, and by laser
densitometry of Southern blots of placental DNA using a range
of autoradiographic exposures.
Preparation of RNA
Frozen fetal livers were homogenized in 1.5 ml of6M urea, 3M
LiCl for approximately 60 seconds and sonicated for 1 minute.
RNA was allowed to precipitate overnight at 4°C and collected
by centrifugation at lOg for 30 minutes at 4°C (27). Pellets were
washed once in the same solution, dissolved in 10mM Tris HCl
(pH 7.5), 0.5% SDS, phenol-chloroform extracted and ethanol
precipitated.
Si nuclease protection assay
Globin RNA was analyzed by Sl nuclease protection assay
(28,29). Probes were end labelled with T4 polynucleotide kinase.
Twenty to thirty nanograms of labelled probe was hybridized to
approximately 5Itg of total fetal liver RNA in a total of 151d of
40mM Pipes (pH 6.4), 400mM NaCl, 1mM EDTA and 80%
formamide for 16 hours at 53°C. Samples were digested for 2
hours at 25°C with 100 u of SI nuclease (Boehringer) in 250,1L
of 200mM NaCl, 30mM NaOAc (pH 4.5), 2mM ZnSO4. The
protected DNA was phenol-chloroform extracted, ethanol
precipitated and electrophoresed on 6% urea-polyacrylamide gels.
Individual bands were excised from the gel after autoradiography
and Cerenkov counted. Probe specific activity was corrected by
normalizing the ratio of human 3-globin RNA to mouse globin
RNA in Hull MEL cells to 0.5.
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RESULTS
Generation of transgenic mice containing (-globin DCR
deletion constructs
The original f-globin DCR construct consisted of 21kb ofDNA
encompassing the four erythroid-specific DNaseI hypersensitive
sites located upstream of the e-globin gene (15) (Fig. la,b). This
was subsequently reduced to a 6.5kb cassette construct in which
DNA fragments containing the individual hypersensitive sites
were cloned into a synthetic polylinker and flanked by unique
restriction sites (18,24) (Fig. Ic). Various deletion mutants were
then produced by removal of one or three of the sites (Fig. ld).
Plasmid constructs were restricted with SstII and purified from
vector sequences on agarose gels. DNA fragments were
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Fig. 2: Mosaic screening. Transgenic fetuses were screened for mosaicism by
comparing the ,B-globin copy number from three different tissues. DNA from
placenta (P), body (B) and head (H)was digested with BglII and Southern blotted.
Blots were hybridized with Hu-(3 and NF-H probes as described in the text. This
figure illustrates the three types of transgenic fetuses typically observed. Fully
transgenic fetus (354); mosaic transgenic fetuses, placenta copy number higher
than body and head (360), placenta copy numbers lower than body and head (362).
microinjected at 1-2 /tg/ml into the pronucleus of fertilized
mouse eggs and re-implanted into pseudopregnant females.
Fetuses were collected at 13.5 days of gestation, DNA was
prepared from individual placentas and screened for the presence
of the transgene by polymerase chain reaction (PCR) (30) and/or
Southern blotting (31).
Mosaic Screeiing
Mosaicism is a common and misleading problem in analyzing
expression levels in first generation transgenic fetuses (or mice).
Accurate quantitation of expression levels per gene copy relies
heavily on each cell of an expressing tissue having the same copy
number. It is therefore critical that every possible step be taken
to identify and exclude mosaic mice from the final analysis. We
have found that the most reliable (though not completely infallible)
method of identifying mosaic fetuses is by comparing the
transgene copy number among at least three different tissues.
Fetuses positive for placental DNA were therefore further
analyzed to distinguish true transgenics from mosaic mice. DNA
was prepared from head and body from each transgenic fetus,
digested with BglIl and Southern blotted alongside placental
DNA. The blots were hybridized with a BamHI/ EcoRI probe
from IVS II of the human ,B-globin gene and the single copy
mouse neurofilament heavy chain (NF-H) cDNA as a loading
control. Fetuses in which the transgene copy number varied
between tissues were considered to be mosaic (Fig. 2).
Copy Number Determination
The copy number of non-mosaic transgenic fetuses was
determined by Southern blot analysis of placental DNA as
described above. The ,B-globin and NF-H specific bands in each
lane of the autoradiograms were scanned with a laser densitometer
and the ,3-globin signal was normalized with the value obtained
TABLE 1: EXPRESSION OF it-LOCUS DELETION CONSTRUCTS IN TRANSGENIC MICE
Construct Tg no. cpm Hui3 cpm MO3 HujS/Mfl Copy no. Hufl/Mj3/
Copy no.
HS: 1 140 1189 1751 0.68 5 0.14
163 1471 1466 1.0 6-8 0.15
174 119 266 0.45 20-25 0.02
HS:2 49 1166 1688 0.69 2 0.34
77 2596 2674 0.97 3 0.32
348 1160 1252 1.32 4 0.33
354 1883 790 2.38 40-50 0.05
HS:3 91 458 1666 0.27 2 0.14
104 2542 4103 0.62 4 0.16
94 5344 7128 0.75 5 0.14
103 8204 3974 2 12-18 0.13
HS:4 208 15 410 0.04 1 0.04
198 27 833 0.033 2 0.02
333 223 466 0.48 7 0.06
335 877 576 1.5 30-40 0.04
210 1222 668 1.8 >60 0.03
HS: 124 188 79 99 0.26 3 0.26
330 1347 1355 0.99 5 0.25
HS: 134 32 100 293 0.34 1 0.34
29 99 47 2.14 7 0.30
CONTROLS
HS: 1234 55 1377 922 1.49 3 0.49
Hu 11 MEL 271 543 0.5 1 0.50
TABLE I: Expression ratios of human ,B-globin RNA to mouse (3-globin RNA. Individual bands from the
S1 gel shown in Fig. 3 were excised and Cerenkov counted. The counts were corrected for background and
adjusted for specific activity to give a ratio of HujO/M(3 of 0.5 for Hull RNA (single human 3-globin gene).
Copy numbers were determined as described in the text.
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Fig. 3: Quantitative SI nuclease protection assay of (-globin DCR deletion mutants. 5,ag of fetal liver RNA from transgenic mice at 13.5 days of gestation was
hybridized to 20-30ng of end-labelled DNA probe and treated with SI nuclease. The 5' human ,B-globin S1 probe yields a protected fragment of 160 nucleotides
(H15'); the 5' mouse 3-major globin protected fragment is 90 nucleotides (Mf35'). Constructs are indicated HSI, HS2, etc., closed triangles indicate mosaic mice.
Controls are, Hull RNA, 55 (fetal liver RNA from transgenic mouse with 3 copies of full A locus), Non Tg, non transgenic mouse fetal liver RNA, 267 and 3 x
267, 5ytg and 15/lg of transgenic fetal liver RNA to show probe excess.
from the NF-H specific band to obtain a relative copy number.
These were arranged in a hierarchy from low to high transgene
copy number and five DNA samples representing this range were
selected. The copy numbers of these samples were then
determined by a series of dilutions made with non-transgenic
DNA to approximate the level of a single copy integrant. The
signal obtained from the Southern blots of the diluted samples
was compared to that of the single copy transgenic number 32
(based on end fragment analysis) and copy numbers were
assigned. These values were then used as a scale in the estimation
of copy numbers of transgenic fetuses in the hierarchy. Copy
numbers ranged from single copy integrants to greater than 60
copies (Table I).
Expression Analysis of the DCR Deletion Mutants
Total RNA was isolated from 13.5 day transgenic fetal livers
and analyzed by quantitative S1 nuclease protection assay with
mixed probes for 5' human 4-globin and 5' mouse j3maj globin
mRNAs (Fig. 3). Total RNA from Hull MEL cells (32) and
13.5 day fetal liver RNA from a transgenic mouse containing
three copies of the fulll microlocus (Fig. ic) were used as controls
(18). After autoradiography, individual bands were excised from
the gel and Cerenkov counted in a scintillation counter. The
expression of human 3-globin was calculated as a ratio of the
endogenous mouse j3_maj globin and normalized per gene copy
of the exogenous gene (Table 1).
Single Site Constructs
Transgenic mice containing single hypersensitive site constructs
express significantly higher levels of 0-globin RNA than those
which contain no DCR hypersensitive sites (Fig. 3 and Table
I). Site 2 expresses highest at nearly 70% of the level of a single
endogenous 03maj globin gene. Site 1 and site 3 confer
approximately 30% of the level. Site 4 transgenics express the
lowest levels of human 13-globin of the single hypersensitive site
constructs at 4-10%. These results differ from those obtained
in stably transformed MEL cell populations in which site 2 and
site 3 provide 60 and 40% respectively, and site 1 and site 4
showed low levels of expression (<10%, 24). Clearly, in
transgenic mice, site 1 is as capable as site 3 in producing high
levels of f-globin RNA.
A distinctive feature of the minilocus (Fig. Ib) and microlocus
(Fig. Ic), aside from providing high level expression of 3-globin
and other linked genes, is position independence. The single site
constructs direct lower levels of 3-globin expression per gene
copy than the full microlocus, but each appears to provide position
independent expression (Table I). The exceptions are mouse 174
(site 1) and mouse 354 (site 2) which express at much lower levels
per copy than transgenics containing identical constructs. There
are several possible explanations for this observation. Firstly,
they could represent mosaics which have not been detected by
our screening procedure. An equally likely explanation is that
the reduced expression per copy in these transgenics is due to
extremely high copy numbers of 20-25 and 40-50 copies
respectively. Similar results were obtained in transgenic mice
with high copies of ,B-globin DCR constructs containing site 3
(25) and site 2 (Philipsen et al., in press) and transfected MEL
cells (Talbot et al., unpubl.). Clearly, the remaining single site
transgenics with the possible exception of the site 4 transgenics,
provide reproducible levels of expression per gene copy and thus
we conclude confer position independence.
Three Site Constructs
Constructs 124 and 134 in which individual sites 3 or 2 have
been deleted express human ,B-globin at lower levels than seen
with the full microlocus (Fig. 3 and Table 1). Neither is
significantly different from the level obtained with site 2 alone.
This shows that sites 2 and 3 are required for full activity, and
suggests that all four sites may be required. In conclusion, none
of the constructs tested in transgenics which contain either single
sites or combinations of three sites provide the full expression
of the g-globin gene observed with the complete DCR.
DISCUSSION
We have previously shown that the full 4-globin minilocus and
microlocus provide position independent, high level expression
of human 3-globin in transgenic mice (15,18). The results
presented here demonstrate that the function of position
independence and copy number dependence can be provided by
the individual sites 1, 2 and 3, and shows that sites 2 and 3 are
required for full expression. This suggests that multiple sites act
synergistically and are needed for the expression of each
individual gene. Consequently, the presence of a number of DCR
elements is not related to the fact that it is a multigene family
per se.
lim
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Our results in the analysis of single site constructs differ from
those obtained in stably transformed MEL cell populations (24)
and transient CAT assays in K562 cells (22) or MEL cells (C-
H. Chang and P. Dierks, pers. comm.). In transient assays, only
site 3 was found to have significant enhancing activity. The results
from stable populations of MEL cells showed that sites 2 and
3 had the strongest activating function. In transgenic mice we
show that site 1 has similar transcriptional activating capacity
as site 3 and that site 2 alone produces the highest levels of
expression, approximately two-fold greater than 1 or 3 alone.
The fact that sites 1, 2 and 3 are each capable of conferring
position independent, copy number dependent expression is in
apparent contrast to the interpretation of other laboratories which
have studied the expression of f-globin-DCR hypersensitive site
3 constructs (site II in their nomenclature) in transgenic mice
(20,25). Those studies however, did not exclude the presence
of mosaic mice. The presence of such mice in those analyses
is further suggested by the use of transgenic fetuses at 16 days,
which is relatively late in the adult globin expression stage, and
will actually select for mosaics. Fully transgenic mice which
express high levels of human ,3-globin do not survive if expression
is not balanced by ct-globin expression (18,19). This probably
explains why other laboratories have failed to find strict copy
number dependent expression.
The expression level of human 13-globin in transgenic fetuses
with high transgene copy numbers appears to occur in a non-
copy number dependent manner. This is particularly obvious in
fetuses 174 (site 1; 20-25 copies) and 354 (site 2; 40-50
copies). This phenomena was also observed by Curtin et al. (25)
in site 3 transgenic fetuses with copy numbers greater than
fourteen and in MEL cells containing high copy number
transgenes (Talbot et al., unpubl.). We feel this may be due to
physical limitations created by tandem integration of several small
DCR constructs. High copy number transgenic fetuses which
contain the full minilocus, which retains the normal spacing of
the hypersensitive sites, still express ,B-globin in a copy number
dependent manner suggesting that trans-acting factors are not
limiting (15). A more likely explanation is that the juxtaposition
of several small DCR constructs creates an unusual chromatin
structure which could extend for hundreds of kilobases, depending
on the copy number. It is possible that such an artificial array
of hypersensitive sites no longer allows each globin gene to be
transcribed optimally.
An unexpected result from these experiments was the finding
that at least the hypersensitive sites 1, 2 and 3 taken individually
direct position independent expression from a linked globin gene.
This apparent redundancy suggests that the sites may operate
independently or have varied functional activities which are
developmentally stage specific. This is suggested by the difference
in activity found for site 1 constructs when assayed by transfection
in adult type MEL cells (24) and the transgenic fetal liver. Mice
containing a site 4 construct are active but only express at low
levels and it is not clear whether it is independent of position
of integration. This is in contrast to the in vivo results obtained
in a patient with y,bo-thalassemia containing site 4 only in which
the i-globin allele in cis is completely silent (33). These results
suggest, therefore, that site 4 may not play an important role
in adult globin expression in the context of the entire locus.
However, its activity may be increased significantly in earlier
developmental stages in conjunction with e- or 'y-globin gene
expression. Likewise, sites 1, 2 and 3 may have different
specificities for different genes at each developmental stage.
One of the aims of this work is to increase the understanding
of the mechanisms underlying globin-DCR interactions and thus
delineate the minimal requirements for efficient expression for
subsequent use in somatic gene therapy constructs/experiments.
Our data shows that at least sites 1, 2 and 3 should be present
and we are presently reducing the size of the individual
hypersensitive sites to minimal core fragments which retain full
activity of the larger fragments presented here (Talbot et al., in
press, Philipsen et al., in press, Hanscombe et al., unpubl.). With
this information we will develop smaller 3-globin DCR constructs
suitable for insertion into retroviral vectors and use in gene
addition experiments and gene therapy.
ACKNOWLEDGEMENTS
We thank Drs. M. Antoniou, D. R. Greaves, and V. Mignotte
for helpful discussions and comments and C. O'Carroll for the
preparation of the manuscript. PF is a recipient of an N.I.H.
postdoctoral fellowship. This work was supported by the Medical
Research Council (UK) and in part by the Cooley's Anaemia
Foundation (USA).
REFERENCES
1. Antoniou, M., deBoer, E., Habets, G. and Grosveld, F. (1988) EMBO J.,
7, 377-384.
2. Behringer, R. R., Hammer, R. E., Brinster, R. L. Palmiter, R.D. and
Townes, T. M. (1987) Proc. Natd. Acad. Sci. U.S.A., 84, 7056-7060.
3. Kollias, G., Hurst, J., deBoer, E. and Grosveld, F. (1987) Nucl. Acids Res.,
15, 5739-5747.
4. Trudel, M., Magram, J., Bruckner, L. and Costantini, F. (1987) Mol. Cell.
Biol., 7, 4024-4029.
5. Wall, L., deBoer, E. and Grosveld, F. (1988) Genes and Devel., 2,
1089-1099.
6. deBoer, E., Antoniou, M., Mignotte, V., Wall, L. and Grosveld, F. (1988)
EMBO J., 7, 4203-4212.
7. Berg, P. E., Williams, D. M., Qian, R-L., Cohen, R. B., Cao, S-X.,
Mittelman, M. and Schechter, A. N. (1989) Nucl. Acids Res., 17,
8833-8852.
8. Trainor, C. D., Evans, T., Felsenfeld, G. and Boguski, M. S. (1990) Nature,
343, 92-96.
9. Tsai, S-F., Martin, D.I.K., Zon, L.I., D'Andrea, A.D., Wong, G.G., and
Orkin, S.H. (1989). Nature, 339, 446-451.
10. Evans, T. and Felsenfeld, G. (1989) Cell, 58, 877-885.
11. Magram, J., Chada, K. and Costantini, F. (1985) Nature, 315, 338-340.
12. Townes, T. M., Lingrel, J. B., Chen, H-Y., Brinster, R. L. and Palmiter,
R. D. (1985) EMBO J., 4, 1715-1723.
13. Kollias, G., Wrighton, N., Hurst, J. and Grosveld, F. (1986) Cell, 46, 89-94.
14. Blom van Assendelft, M., Hanscombe, O., Grosveld, F. and Greaves, D.
R. (1989). Cell, 56, 969-977
15. Grosveld, F., Blom van Assendelft, M., Greaves, D. R. and Kollias, G.
(1987). Cell, 51, 975-985.
16. Tuan, D., Solomon, W., Li, Q. and London, I. M. (1985) Proc. Natl. Acad.
Sci. U.S.A. 82, 6384-6388.
17. Forrester, W. C., Takegawa, S., Papayannopoulou, T., Stamatoyannopoulos,
G. and Groudine, M. (1987) Nucl. Acids Res., 15, 10159-10177.
18. Talbot, D., Collis, P., Antoniou, M., Vidal, M., Grosveld, F. and Greaves,
D. R. (1989) Nature, 338, 352-353.
19. Hanscombe, O., Vidal, M., Kaeda, J., Luzzatto L., Greaves, D.R. and
Grosveld, F. (1989). Genes and Devel., 3, 1572-1581.
20. Ryan, T. M., Behringer, R. R., Townes, T. M., Palmiter, R. D. and Brinster,
R. L. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 37-41.
21. Catala, F., deBoer, E., Habets, G. and Grosveld, F. (1989) Nucl. Acids
Res., 19, 3811-3827.
22. Enver, T., Ebens, A.J., Forrester, W.C., and Stamatoyannopoulos, G. (1989).
Proc. Natl. Acad. Sci. U.S.A. 86, 7033-7037.
23. Tuan, D. Y. H., Solomon, W. B., London, I. M. and Lee, D. P. (1989)
Proc. Natl. Acad. Sci. USA, 86, 2554-2558.
24. Collis, P., Antoniou, M., and Grosveld, F. (1990). EMBO J., 9, 233-240.
3508 Nucleic Acids Research, Vol. 18, No. 12
25. Curtin, P.T., Liu, D., Liu, W., Chang, J.C., and Kan, Y.W. (1989). Proc.
Nail. Acad. Sci. U.S.A. 86, 7082-7086.
26. Hogan, B., Cosatini, F. and Lacy, E. (1986) Manipulating the mouse
embryo. A laboratory manual. Cold Spring Harbor Laboratory.
27. Auffray, C. and Rougeon, F. (1980). Eur. J. Biochem. 107, 303-314.
28. Berk, A. J. and Sharp, P. A. (1977). Cell, 12, 721-732.
29. Weaver, R. and and Weissmn, C. (1979) Nucl. Acids Res., 6, 1175-1192.
30. Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Korn, G. T., Erlich,
H. A. and Arheim, N. (1985) Science, 230, 1350-1354.
31. Southem, E. M. (1975) J. Mol. Biol., 98, 503-517.
32. Zavodny, P., Roginsky, R. an Skoultchi, A. (1983) In: Globin Gene
Expression and Hematopoietic Differentaton. G. Stamatoyannopoulos and
A. Nienhus, Eds. (New York, Ala R. Liss Inc.), pp. 53-62.
33. Driscoll, M. C., Dobkdn, C. S. and Alter, B. P. (1989) Proc. Natl. Acad.
Sci. U.S.A., 86, 7470-7474.
